Immunome, Inc. Shareholders' Equity
Immunome, Inc. (IMNM) had Shareholders' Equity of $525.08 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $525.08M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $588.69M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $634.34M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $263.92M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $525.08M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $588.69M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $634.34M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $263.92M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $269.27M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $307.13M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $181.16M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $214.91M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $253.84M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $285.57M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $119.88M 10-K · filed 2026-03-03 |
| 2023-09-30 | $6.08M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $9.34M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $13.86M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $16.65M 10-K · filed 2025-03-19 |
| 2022-09-30 | $23.08M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $30.28M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $37.87M 10-Q · filed 2023-08-09 |
| 2021-12-31 | $48.19M 10-K · filed 2024-03-28 |
| 2021-09-30 | $54.79M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $60.62M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $37.88M 10-Q · filed 2022-08-05 |
| 2020-12-31 | $41.34M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$49.09M 10-Q · filed 2021-11-15 |
| 2020-06-30 | -$40.83M 10-Q · filed 2021-11-15 |
| 2020-03-31 | -$38.16M 10-Q · filed 2021-08-16 |
| 2019-12-31 | -$35.63M 10-K · filed 2022-03-28 |
| 2019-09-30 | -$32.72M 10-Q · filed 2020-11-16 |
| 2019-06-30 | -$29.98M 10-Q · filed 2020-11-16 |
| 2018-12-31 | -$25.20M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |